In a report released today, Luke Sergott from Barclays maintained a Hold rating on Quest Diagnostics (DGX – Research Report), with a price ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics by financial experts. The following summary presents ...

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...

Barclays upped their price target on shares of Quest Diagnostics from $168.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Friday, January 31st. StockNews.com ...

In addition to Barclays, Quest Diagnostics also received ... Baird maintained a Buy rating on Quest Diagnostics (NYSE: DGX). The company has a one-year high of $178.87 and a one-year low of ...

Stay informed and make data-driven decisions with our Ratings Table. Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company ...